Fisher Scientific
This article was originally published in The Gray Sheet
Executive Summary
Life-sciences and biochemicals segments are bolstered through acquisition of Oxoid Group Holdings for $330 mil. and Dharmacon for $80 mil. under separate definitive agreements. Oxoid adds $155 mil. in revenue from microbiological culture media and other products to test for bacterial contamination, used in research labs, drug production and process validation. Dharmacon, with sales of $17 mil., provides RNA-based products for life science research and drug discovery. "We anticipate sales of higher-margin, proprietary products to increase from 45% to approximately 50% of total sales as a result of these acquisitions," Fisher says...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.